On one hand, multiple observational studies have demonstrated that statins have the potential to decrease the risk of cancer and cancer‐related mortality.[49, 50, 51] On the other hand, phase III studies have indicated that statins do not provide any clinical benefits for patients with gastric cancer and HCC.[52, 53] In our study, both the removal and addition of cholesterol manipulation indicated that exogenous cholesterol induced MET phosphorylation and metastasis of HCC cells, while cholesterol removal suppressed MET activation and blocked RNASET2 deletion‐mediated EMT and invasion. Here, RNASET2 is linked to gastric cancer.